FCF Yield

AstraZeneca's current Free Cash Flow (FCF) Yield of 3.0% means the company generates $0.03 in free cash flow for every dollar of its stock price, a measure of the cash return an investor receives relative to the share cost.

This yield sits below the healthcare sector median of 3.6%, placing AstraZeneca in the 44th percentile among its sector peers, so it is slightly weaker than the typical peer. The metric has been decreasing over the last eight quarters, with a quarter-over-quarter decline of -6.3% (year-over-year change is not available), indicating a steady erosion in this cash return measure. The combination of a below-median level and a declining trend points to increased investment risk, as the company is generating less cash relative to its price while that relative return continues to shrink. This metric contradicts the overall NEUTRAL verdict, as a falling and below-peer FCF Yield typically signals a less attractive investment profile that would lean bearish rather than neutral.

Frequently Asked Questions

Closest Sector Peers